OmnicellOMCL
About: Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
Employees: 3,670
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
49% more call options, than puts
Call options by funds: $2.7M | Put options by funds: $1.81M
13% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 89
0.34% more ownership
Funds ownership: 99.81% [Q4 2024] → 100.15% (+0.34%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
3% less funds holding
Funds holding: 276 [Q4 2024] → 269 (-7) [Q1 2025]
11% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 38
20% less capital invested
Capital invested by funds: $2.06B [Q4 2024] → $1.64B (-$422M) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Wells Fargo Stan Berenshteyn | 28%upside $35 | Overweight Upgraded | 14 May 2025 |
Benchmark Bill Sutherland | 46%upside $40 | Buy Maintained | 7 May 2025 |
JP Morgan Anne Samuel | 32%upside $36 | Neutral Maintained | 20 Mar 2025 |
Financial journalist opinion
Based on 10 articles about OMCL published over the past 30 days
